MatsukiyoCocokara & Co.

MatsukiyoCocokara & Co.

MSMKF
MatsukiyoCocokara & Co.US flagOther OTC
18.17
USD
- -
- -
7.23BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,604
1,525.46
1,501.66
1,665.8
1,676.34
1,760.47
1,836.11
1,918.06
1,768.91
1,991.9
2,252.77
2,447.77
2,598.97
1,234.77
Basic EPS, GAAP
39.62
41.12
35.94
55.48
63.02
71.68
79.81
85.01
70.15
93.81
96.02
125.31
133.85
63.59
Free Cash Flow per Basic Share
48.94
64.19
10.29
78.25
57.56
72.59
52.12
60.2
66.92
78.71
112.05
103.88
164.06
- -
Dividend per Share
8.16
9.9
10.04
11.66
14.78
16.69
20.26
23.36
23.36
22.57
25.06
31.72
41.2
- -
Book Value per Share
404.9
387.35
413.73
459.5
511.19
569.03
635.39
708.98
754.78
693.38
672.7
773.56
883.74
814.97
Tangible Book Value per Share
444.24
416.63
445.45
494.45
539.06
610.69
635.52
714.17
770.67
864.37
816.47
914.37
963.23
888.71
Basic Weighted Avg Shares
284
325
323
322
319
317
314
308
308
366
422
418
408
417
Sales/Revenue/Turnover
456,311
495,385
485,512
536,052
535,133
558,879
575,991
590,593
544,737
729,969
951,247
1,022,531
1,061,626
514,765
Operating Margin (%)
4.32
4.53
3.63
5.12
5.31
6.01
6.26
6.36
5.8
5.63
6.55
7.4
7.73
7.41
Depreciation Expense
6,024
6,420
7,157
7,569
7,945
7,704
8,233
8,403
8,578
14,861
20,840
22,367
22,599
- -
Net Income, GAAP
11,270
13,355
11,619
17,853
20,119
22,755
25,035
26,176
21,602
34,377
40,545
52,347
54,675
26,509
Effective Tax Rate (%)
41.2
40.82
40.39
33.84
30.18
33.88
33
33.02
33.87
30.24
37.19
35.24
34.43
34.89
Profit Margin (%)
2.47
2.7
2.39
3.33
3.76
4.07
4.35
4.43
3.97
4.71
4.26
5.12
5.15
5.15
Working Capital
20,347
26,768
30,149
45,271
58,484
72,638
77,114
73,825
90,445
155,766
176,538
191,370
201,676
179,549
LT Debt
2,428
2,752
2,662
2,742
2,710
2,996
3,905
22,176
21,719
20,280
19,298
588
607
- -
Total Equity
137,106
150,625
158,296
171,639
184,058
204,869
209,267
229,303
246,218
460,128
482,715
515,174
521,497
501,052
Return on Invested Capital (%)
8.02
8.55
6.42
10.42
10.56
10.79
10.97
10.41
7.79
7.44
7.72
9.15
9.84
4.63
Return on Capital (%)
8.74
10.41
8.56
12.27
12.6
12.91
12.83
11.7
8.68
12.9
13.85
16.04
15.36
7.73
Return on Common Equity (%)
10.04
11.08
8.95
12.68
12.94
13.24
13.18
12.54
9.59
14.13
15.07
17.24
15.98
8.24

Capital Structure

FRC

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
20,075
- -
19,464
LT Borrowings
- -
- -
- -
LT Finance Leases
588
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
417
- -
404
Market Capitalization
- -
- -
1,029,498

Working Capital

FRC

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
370,798
- -
355,143
Cash, Cash Equivalents & STI
117,720
- -
113,394
Accounts Receivable, Net
61,747
- -
57,940
Inventories
139,352
- -
142,147
Total Current Liabilities
179,428
- -
175,594
Payables & Accruals
- -
- -
- -
ST Debt
20,075
- -
19,464
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.58%
21.42%
1.23%
Free Cash Flow
80.09%
32.27%
54.44%
Net Income, GAAP
18.72%
18.63%
4.45%
Sales/Revenue/Turnover
8.81%
13.57%
3.82%
Total Cash Common Dividend
18.19%
19.04%
27.01%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
248,222
259,544
262,567
252,198
1,022,531
2025
- -
- -
- -
- -
1,061,626
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28.69
- -
- -
- -
125.31
2025
- -
- -
- -
- -
133.85
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
31.72
2025
- -
- -
- -
- -
41.2
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Kiyoo Matsumoto
Full Time Employees
13,371
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
9-1 Shinmatsudo-Higashi Matsudo Japan 270-8511
IPO Date
Jun 27, 2014
Business
MatsukiyoCocokara & Co. (ticker: MSMKF), founded in 1932 through predecessor entities and headquartered in Tokyo, Japan, operates as Japan's leading health and beauty retailer, managing over 3,400 drugstores, insurance-dispensing pharmacies and franchise outlets nationwide through segments including the Matsumotokiyoshi Group Business, Cocokara Fine Group Business and Management Support Business. The company retails pharmaceuticals, over-the-counter medications, prescription drugs, cosmetics, beauty care products, health foods, personal care items, supplements, household necessities and private brand goods; it also provides wholesale distribution of medicines and daily goods to retailers and healthcare providers, franchise development and support services encompassing IT infrastructure, human resources, finance, marketing, advertising, promotion, asset management, store construction and insurance agency operations. Operations span Japan with overseas expansion in Asia including 79 stores in Singapore, Macao and Malaysia as of March 2025, targeting ASEAN markets and inbound travelers through proprietary brands and services such as MatsukiyoCocokara Q store-to-home delivery, MatsukiyoCocokara Me digital pharmacy app, MatsukiyoCocokara Be EC beauty platform with makeup simulation and skin/hair assessments, MatsukiyoCocokara Up personalized supplement subscriptions and on-demand delivery using electric vehicles. In October 2021, the company changed its trade name from Matsumotokiyoshi Holdings Co., Ltd. following the management integration with cocokara fine Inc., achieving merger synergies of 30 billion yen and surpassing prior medium-term targets early with FY2024 net sales of 1,061.6 billion yen, operating profit margin of 7.7% and ROE of 10.6%. On May 9, 2025, MatsukiyoCocokara unveiled a new medium-term management plan through FY2030 emphasizing co-creating value via differentiation through platform enhancements like one-to-one marketing and 45 million registered customers, investments totaling around 160 billion yen in store openings/renovations, IT/digital transformation, small-to-medium M&As, alliances, human capital, overseas growth aiming for 100 billion yen in overseas sales and carbon neutrality initiatives, alongside 45% cash allocation to growth and shareholder returns targeting 50% dividend payout, 6% DOE and ROE over 12%.